Published in Lab Business Week, May 6th, 2007
The allowed claims relate to both use and composition of KP-1461, an oral small molecule currently in clinical trials to treat HIV infection. KP-1461 utilizes a novel therapeutic mechanism, Viral Decay Acceleration (VDA), that works by increasing the virus' naturally high mutation rate. The accumulation of mutations throughout the viral genome exceeds an error threshold and leads to viral collapse. In vitro experiments have...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Lab Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.